Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

ght, Director of Research and Development at GW. "We believe this clinical program demonstrates the flexibility and broad application of GW's cannabinoid platform to treat significant, unmet therapeutic needs." 

This study is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. The study objective is to assess the tolerability, safety and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ratio, in combination with temozolomide in patients with recurrent GBM. Secondary endpoints include additional pharmacokinetic and biomarker analyses and additional measurable outcomes of tumor response.

References:

i. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):319-32.
ii. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3(10):745-55.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world l
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Berkshire Corporation, the world leader ... the release of the ValuSeal® IonX™ cleanroom wiper, ... containment in critical processing applications. , Recommended for ... environments, ValuSeal® IonX™ is a laser sealed edge ... continues Berkshire’s innovative focus on meeting new challenges ...
(Date:10/25/2014)... ROCKVILLE, Md. , Oct. 24, 2014  RegeneRx Biopharmaceuticals, ... on data presented at the Fourth International Symposium on ... , Italy.  "When thymosin beta ... was injected into the peritoneal cavity in a rodent ... vessels and throughout the brain parenchyma (the functional tissue ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... , ... Have Clear Goals, Timeline and Roles , ... Canberra, Australia (Vocus) October 27, 2009 -- Global food security, ... fully achieved through well-designed and executed public and private partnerships, William S. Niebur ...
... Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization ... Virus." The patent claims cover methods of using ... to treat patients that are refractory to those ...
... Md., Oct. 27 Precision Antibody(TM) has ... of the National Cancer Institute (NCI),s Clinical Proteomic Technologies ... number and standardizing the quality of monoclonal antibody reagents ... is the result of a third solicitation for contract ...
Cached Biology Technology:Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... illnesses have triggered calls for more regulation along ... University of Minnesota this week will explore the ... "How Safe is our Food Supply? Expectations, Technology, ... p.m. Wednesday, April 1, at Coffman Memorial Hall, ...
... GAITHERSBURG, Md.Researchers at the Commerce Department,s National Institute ... have capitalized on a process for manufacturing integrated ... level and used it to develop a method ... with complex three-dimensional surfaces. As described ...
... Swedish medical university Karolinska Institutet (KI) have constructed a mathematical ... increase the understanding of the capacity of the working memory ... interact. One of the findings they have made with this ... that restricts the number of items we can normally store ...
Cached Biology News:NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 2NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 3NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 4Computer simulations explain the limitations of working memory 2